Targeted Neuromodulation for Obsessive-Compulsive Disorder

Recruiting in Palo Alto (17 mi)

Overseen byBrian P Brennan, MD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Mclean Hospital

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial investigates whether a magnetic treatment can help people with OCD who have contamination/washing symptoms. The treatment uses magnetic fields to stimulate brain cells and aims to reduce overactivity in specific brain areas to alleviate these symptoms. This method has been approved for treating depression and OCD.

Eligibility Criteria

This trial is for adults aged 18-55 with Obsessive-Compulsive Disorder (OCD), specifically those who struggle mainly with contamination/washing symptoms. Participants should score ≥8 on a specific OCD scale and not have started new therapy or changed medications recently. It's not open to individuals using certain psychiatric drugs, those with a recent substance use disorder, or anyone pregnant.

Inclusion Criteria

Score of ≥ 8 on Dimension 4 of the D-YBOCS

I am not on psychiatric meds or have been on a stable dose for 4 weeks.

CONTAM as the predominant symptom dimension

+3 more

Exclusion Criteria

I am not taking any psychiatric medications not allowed in this study.

Positive urine drug screen (other than prescribed benzodiazepines)

Substance use disorder in the last 3 months (with the exception of nicotine)

+5 more

Participant Groups

The study tests individually targeted neuromodulation techniques: iTBS and cTBS against a sham procedure to see if they can reduce contamination-based OCD symptoms more effectively than current general treatments.

3Treatment groups

Experimental Treatment

Placebo Group

Group I: iTBSExperimental Treatment1 Intervention

intermittent TBS to right MFG

Group II: cTBSExperimental Treatment1 Intervention

continuous TBS to right MFG

Group III: shamPlacebo Group1 Intervention

sham stimulation to right MFG

cTBS is already approved in United States for the following indications:

🇺🇸 Approved in United States as cTBS for: